ProPublica Highlights Regulatory Investigations in Hemp, Lending, and Healthcare
This ProPublica archive page highlights recent investigative reporting focused on regulatory failures and enforcement actions across various sectors. Key stories include Colorado regulators cracking down on intoxicating hemp products due to public safety risks and tax avoidance concerns. Another major report details the Trump Department of Justice's controversial plan to settle a predatory lending case without compensating victims, a move criticized as harming the Hispanic residents originally defrauded. Additionally, investigations reveal that a prominent Kentucky drug rehabilitation center may have prioritized profit over patient care, potentially engaging in fraud. The page also covers potential regulatory reversals by RFK Jr. regarding peptide bans, contested by former FDA officials. These reports underscore systemic issues in consumer protection, healthcare oversight, and financial regulation. The content emphasizes the impact of journalistic scrutiny on policy changes, such as proposed amendments to laboratory testing standards and prescription medication labeling. By exposing conflicts of interest and corporate malfeasance, these investigations aim to hold government officials and private entities accountable for public safety and ethical conduct.
Wire timeline
ProPublica Highlights Regulatory Investigations in Hemp, Lending, and Healthcare
This ProPublica archive page highlights recent investigative reporting focused on regulatory failures and enforcement actions across various sectors. Key stories include Colorado regulators cracking down on intoxicating hemp products due to public safety risks and tax avoidance concerns. Another major report details the Trump Department of Justice's controversial plan to settle a predatory lending case without compensating victims, a move criticized as harming the Hispanic residents originally defrauded. Additionally, investigations reveal that a prominent Kentucky drug rehabilitation center may have prioritized profit over patient care, potentially engaging in fraud. The page also covers potential regulatory reversals by RFK Jr. regarding peptide bans, contested by former FDA officials. These reports underscore systemic issues in consumer protection, healthcare oversight, and financial regulation. The content emphasizes the impact of journalistic scrutiny on policy changes, such as proposed amendments to laboratory testing standards and prescription medication labeling. By exposing conflicts of interest and corporate malfeasance, these investigations aim to hold government officials and private entities accountable for public safety and ethical conduct.
propublica